960535-39-1

Basic information

• Product Name: 2-CHLORO-5,6-DIFLUOROBENZOTHIAZOLE
• Synonyms: 2-CHLORO-5,6-DIFLUOROBENZOTHIAZOLE;2-Chloro-5,6-difluorobenzo[d]thiazole 2-Chloro-5,6-difluorobenzo[d]thiazole;2-chloro-5,6-difluorobenzo[d]thiazole
• CAS NO: 960535-39-1
• Molecular Formula: C7H2ClF2NS
• Molecular Weight: 205.6122864
• Mol File: 960535-39-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-CHLORO-5,6-DIFLUOROBENZOTHIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-5,6-DIFLUOROBENZOTHIAZOLE(960535-39-1)
• EPA Substance Registry System: 2-CHLORO-5,6-DIFLUOROBENZOTHIAZOLE(960535-39-1)

Safety Data

• Hazardous Substances Data: 960535-39-1(Hazardous Substances Data)

Usage

General Description

2-Chloro-5,6-difluorobenzothiazole is a chemical compound with the molecular formula C7H2ClF2NS. It is a synthetic intermediate used in the production of pharmaceuticals, agrochemicals, and other specialty chemicals. 2-CHLORO-5,6-DIFLUOROBENZOTHIAZOLE is a potent inhibitor of the androgen receptor and has potential applications in the treatment of hormone-related disorders, such as prostate cancer. It is also used as a building block in the synthesis of various organic compounds, including benzothiazole derivatives and fluorescent dyes. 2-Chloro-5,6-difluorobenzothiazole is a versatile chemical with a wide range of industrial and research applications.

Upstream product

• 1188090-42-7 C₇H₅F₂N₃S 
• 352214-93-8 SKA-42 
• 3863-11-4 3,4-difluoroaniline 

Relevant articles and documents

Preparation, antibacterial evaluation and preliminary structure-activity relationship (SAR) study of benzothiazol- and benzoxazol-2-amine derivatives

In this study, a novel benzothiazol- and benzooxazol-2-amine scaffold with antibacterial activity was designed and synthesized. Preliminary structure-activity relationship analysis displayed that compound 8t with a 5,6-difluorosubstituted benzothiazole was found to be a potent inhibitor of Gram-positive pathogens, and exhibited some potential against drug-resistant bacteria and without cytotoxicity in therapeutic concentrations. In addition, molecular docking studies indicated that Staphylococcus aureus methionyl-tRNA synthetase might be the possible target of these compounds. Taken together, the present study provides an effective entry to the synthesis of a good lead for subsequent optimization and a new small molecule candidate drug for antibacterial therapeutics.